Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817995 | 0.85 | TDP1 (0.66) | MAPTTDP1PDE4DPOLBMAPK1 | |
| SCHEMBL31346670 | 0.85 | MAPT (0.51) | MAPTTDP1PDE4DPOLBMCL1 | |
| SCHEMBL222062 | 0.85 | MAPT (0.55) | MAPTTDP1PDE4DMCL1MEN1 | |
| SCHEMBL8492183 | 0.85 | POLB (0.42) | MAPTTDP1PDE4DPOLBMCL1 | |
| SCHEMBL10407306 | 0.84 | TDP1 (0.50) | MAPTTDP1PDE4DPOLBMCL1 | |
| SCHEMBL23067280 | 0.83 | CTSD (0.54) | MAPTTDP1PDE4DLMNAMEN1 | |
| SCHEMBL7696483 | 0.82 | MAPT (0.40) | MAPTTDP1PDE4DPOLBMCL1 | |
| SCHEMBL1748844 | 0.81 | RAB9A (0.42) | MAPTTDP1PDE4DLMNAMAPK1 | |
| SCHEMBL11281015 | 0.81 | ALDH1A1 (0.38) | MAPTTDP1PDE4DPOLBLMNA | |
| SCHEMBL7696487 | 0.81 | MEN1 (0.40) | MAPTTDP1PDE4DSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-13 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| CN-110498784-A | A kind of Nobiletin derivative or its pharmaceutically acceptable salt and its preparation method and application | ZHIYUAN MEDICINE TECH QINGYUAN CO LTD | 2019-11-26 | — | — | CN | disclosed |
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | RACHWAL STANISLAW (US) | 2003-12-11 | — | — | US | disclosed |
| US-6509366-B2 | Substituted imidazoles as selective modulators of Bradykinin B2 receptors | NEUROGEN CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION | 2002-08-22 | — | — | US | disclosed |
| US-6420365-B1 | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-6358949-B1 | CARDIOVASCULAR AND SEXUAL DISORDERS; DIABETES, KIDNEY DISEASE, LIVER CIRRHOSIS; ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIASTHMATICS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| WO-2001056995-A1 | SUBSTITUTED IMIDAZOLES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS | NUEROGEN CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001053298-A1 | IMIDAZOPYRIDINES AND RELATED AZACYCLIC DERIVATIVES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS | NEUROGEN CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | MAPT 3175/4885TDP1 3929/4885PDE4D 2692/4885 |
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, HRH2 | MAPT 3419/4885TDP1 4305/4885PDE4D 1877/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | MAPT 3146/4885TDP1 1223/4885PDE4D 2819/4885 |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | MAPT 3044/4885TDP1 3822/4885PDE4D 2642/4885 |
| US-20230114728-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | MAPT 3146/4885TDP1 1223/4885PDE4D 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.